BERKELEY, Calif.–(BUSINESS WIRE)–Mar 19, 2013–DSM, a global leader in biomedical materials science, today announced that the company has signed a license and supply agreement with spinal implant and surgical systems developer, SpineVision ®.
The agreement grants SpineVision ® the use of Bionate ® II PCU, a proprietary DSM polymer, in its new Flex ± 2™ system. The system is adaptable to the various stages of disc degeneration from early degeneration of intervertebral discs to total disc degeneration requiring fusion procedures. This level of flexibility not only offers spine surgeons more options in the treatment of lumbar disc diseases, but also allows selective segmental stabilization to better treat disc degeneration throughout multiple stages.
The Flex + 2™ system utilizes a top-loading, top-tightening design, which accommodates both open and percutaneous approaches. DSM’s Bionate ® II PCU encapsulates the metal wire and provides the system with enhanced frontal and sagittal stabilization, assuring flexion and extension, which allow for increased freedom of movement and better accommodation to the spine without loss of strength or stability.
“The combination of design changes and the use of Bionate ® II PCU have enabled SpineVision ® to enhance the mechanical capabilities of the new Flex + 2 TM system leading to extended indications” said Arnaud Brisard, Chief Executive Officer, SpineVision ®.
“DSM’s polyurethane materials have a proven clinical history and have been used in several dynamic stabilization devices and implants,” said William Fuller, Director of Business Development, DSM Biomedical. “Our Bionate®II PCU provides increased flexibility and shock absorbing characteristics, replicating the natural movements of the spine. We are proud to see Bionate® II PCU contributing to the performance of SpineVision’s Flex+2 ™ system.” SpineVision ® will initially launch the Flex + 2™ system in the European Union. The device is not currently available for sale in the U.S.
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 23,500 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.
About SpineVision ®
SpineVision ® is a privately owned medical device company focused on the development and commercialization of innovative products for use in spinal surgery. The Company develops and markets a proprietary suite of implants addressing a wide range of spinal pathologies including deformity, cervical disorders, lumbar DDD and trauma. Because of market opportunity and the quality of its product lines, SpineVision ® decided in 2008 to focus its efforts on a new approach of fusion combining Dynamic Stabilization and Minimally Invasive Surgery. SpineVision ® enjoys very strong relationships with preeminent international spine surgeons and key opinion leaders. Their direct involvement in new product development, evaluation and promotion has ensured that the Company’s products feature innovative designs that serve to improve surgical techniques for physicians, clinical outcomes for patients and efficiencies for health care providers. The Company is headquartered in Antony, France, and has subsidiaries in the USA, Italy, UK and Belgium. More information can be found at: www.spinevision.net.
